EnTrega Platform for Leptomeningeal Carcinomatosis

About EnClear Therapies

EnClear Therapies, founded in 2019 and based in Cambridge, USA, is a private, pre-revenue biotech company developing a novel platform for CNS drug delivery. Its core technology, the EnTrega CSF Platform, is designed to enable controlled, continuous, and personalized delivery of therapeutics directly into the cerebrospinal fluid (CSF), aiming to overcome the blood-brain barrier and improve efficacy while reducing systemic toxicity. The company's initial focus is on addressing a significant unmet need in neuro-oncology, specifically leptomeningeal carcinomatosis, with plans to expand into broader neurodegenerative and rare CNS disorders through strategic partnerships.

Therapeutic Areas